Hepatothermic therapy of obesity: Rationale and an inventory of resources

Medical Hypotheses

Volumn 57, Issue 3, 2001, Pages 324-336

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BIOTIN; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CHROMIUM; CILOSTAZOL; DIAZOXIDE; FIBRIC ACID DERIVATIVE; FISH OIL; GLUCAGON; HYDROXYCITRIC ACID; ICOSAPENTAENOIC ACID; INSULIN; LINOLEIC ACID; METFORMIN; OXALOACETIC ACID; PANTETHINE; POLYPHENOL; PRASTERONE; PYRUVIC ACID; SESAMIN; UBIQUINONE;

AEROBIC METABOLISM; ARTICLE; DIET SUPPLEMENTATION; ENZYME ACTIVATION; EXERCISE; FATTY ACID OXIDATION; GLUCOGENESIS; GLUCOSE INTAKE; HUMAN; LIFESTYLE; LIVER METABOLISM; LOW FAT DIET; MITOCHONDRIAL RESPIRATION; OBESITY; PRIORITY JOURNAL; PROTEIN DIET; RESPIRATORY QUOTIENT; THERMOGENESIS;

EID: 0034829420     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1322     Document Type: Article

References (169)

1. Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids
2. Oxaloacetate deficiency in MCT-induced ketogenesis
3. Ketogenesis from oleate and octanoate in isolated rat hepatocytes
4. Role of the mitochondrial metabolism of pyruvate on the regulation of ketogenesis in rat hepatocytes
5. Relationship between the stimulation of citric acid cycle oxidation and the stimulation of fatty acid esterification and inhibition of ketogenesis by lactate in isolated rat hepatocytes
6. Effect of palmitate concentration on the relative contributions of the beta-oxidation pathway and citric acid cycle to total O2 consumption of isolated rat hepatocytes
7. The regulation of ketogenesis
8. Role of carnitine in hepatic ketogenesis
9. Differences in the sensitivity of carnitine palmitoyltransferase to inhibition by malonyl-CoA are due to differences in Ki values
10. Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA abundance of hepatic carnitine palmitoyltransferase-I
11. The contribution of hepatic metabolism to diet-induced thermogenesis
12. Evidence for liver as the major site of the diet-induced thermogenesis of rats fed a "cafeteria" diet
13. Brown adipose tissue, liver, and diet-induced thermogenesis in cafeteria diet-fed rats
14. Metabolic origins of thermogenesis induced by diet
15. Influence of diet composition on serum triiodothyronine (T3) concentration, hepatic mitochondrial metabolism and shuttle system activity in rats
16. The role of the liver in non-shivering thermogenesis in the rat
17. +-ATPase activity in rat liver
18. Effects of thyroid states on the Cori cycle, glucose-Alanine cycle, and futile cycling of glucose metabolism in rats
19. Role of brown adipose tissue in thermogenesis induced by overfeeding a diet containing medium chain triglyceride
20. Concerning the mechanism of increased thermogenesis in rats treated with dehydroepiandrosterone
21. The calorigenic nature of hepatic ketogenesis: An explanation for the stimulation of respiration induced by fatty acid substrates
22. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes
23. Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice [correction of rat] liver
24. Transition from the polikilotherm to the homeotherm: Possible role of sodium transport and thyroid hormone
25. Stimulation by thyroid hormone of coupled respiration and of respiration apparently not coupled to the synthesis of ATP in rat hepatocytes
26. Regulation of carnitine palmitoyltransferase in vivo by glucagon and insulin
27. Cyclic AMP and fatty acids increase carnitine palmitoyltransferase I gene transcription in cultured fetal rat hepatocytes
28. Effects of dietary alpha-linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and beta-oxidation in rats
29. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference
30. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism
31. The hypotriglyceridemic effect of eicosapentaenoic acid in rats is reflected in increased mitochondrial fatty acid oxidation followed by diminished lipogenesis
32. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation
33. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference
34. Regulation of triglyceride metabolism by PPARs: Fibrates and thiazolidinediones have distinct effects
35. In support of the roles of malonyl-CoA and carnitine acyltransferase I in the regulation of hepatic fatty acid oxidation and ketogenesis
36. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes
37. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose
38. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes
39. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mrnas
40. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats
41. Coordinate regulation of glycolytic and lipogenic gene expression by polyunsaturated fatty acids
42. Hepatic lipogenesis in young rats given proteins of different quality
43. Effects of dietary proteins on lipogenic enzymes in rat liver
44. Soybean protein suppresses hepatic lipogenic enzyme gene expression in Wistar fatty rats
45. Sesamin, a sesame lignan, is a potent inducer of hepatic fatty acid oxidation in the rat
46. Reciprocal effects of dietary sesamin on ketogenesis and triacylglycerol secretion by the rat liver
47. Inhibition of cholesterol absorption and synthesis in rats by sesamin
48. Sesame lignans modulate cholesterol metabolism in the stroke-prone spontaneously hypertensive rat
49. Hypocholesterolemic effect of sesame lignan in humans
50. Tricarballylate and hydroxycitrate: Substrate and inhibitor of ATP: Citrate oxaloacetate lyase
51. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat
52. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. II. Appetite
53. Effect of (-)-hydroxycitrate on development of obesity in the Zucker obese rat
54. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial
55. (-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorprive state
56. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase
57. Acute hormonal control of acetyl-CoA carboxylase. The roles of insulin, glucagon, and epinephrine
58. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-acrivated protein kinase
59. Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation
60. Effects of pantethine on lipogenesis and CO2 production in the isolated hepatocytes of the chick (Gallus domesticus)
61. Inhibition of acetyl-CoA carboxylase by cysteamine may mediate the hypotriglyceridemic activity of pantethine
62. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment
63. Hormonal control of fatty acid oxidation during the neonatal period
64. The adaptive effects of dietary fish and safflower oil on lipid and lipoprotein metabolism in perfused rat liver
65. Enhanced uptake of carnitine by perfused rat liver following starvation
66. Effect of insulin and glucagon on the uptake of carnitine by perused rat liver
67. Orthomolecular aids for dieting
68. High glycemic index foods, overeating, and obesity
69. The glycemic index
70. Post-exercise ketosis and the hormone response to exercise: A review
71. Exercise, glucose transport, and insulin sensitivity
72. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes
73. The effect of chromium supplementation on carbohydrate metabolism and body composition
74. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors
75. Effect of dietary protein on serum insulin and glucagon levels in hyper- and normocholesterolemic men
76. Plasma amino acids and the insulin/glucagon ratio as an explanation for the dietary protein modulation of atherosclerosis
77. Vegan proteins may reduce risk for cancer, obesity, and cardiovascular disease by promoting increased glucagon activity
78. Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity
79. Energy balance: Interpretation of data from rural China
80. Membrane physical properties do not explain increased cyclic AMP production in hepatocytes from rats fed menhaden oil
81. + channels in mouse pancreatic beta-cells
82. Beneficial effect of diazoxide in obese hyperinsulinemic adults
83. Antiobesity effect of diazoxide in obese Zucker rats
84. Modification of insulin resistance by diazoxide in obese Zucker rats
85. Prophylaxis of genetically determined diabetes by diazoxide: A study in a rat model of naturally occurring obese diabetes
86. Effect of pharmacological suppression of insulin secretion on tissue sensitivity to insulin in subjects with moderate obesity
87. Effects of dexamethosone and glucagon after long-term exposure on cyclic AMP phosphodiesterase 4 in cultured rat hepatocytes
88. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family)
89. Type III cyclic nucleotide phosphodiesterases and insulin action
90. Combined effects of insulin and dexamethasone on cyclic AMP phosphodiesterase 3 and glycogen metabolism in cultured rat hepatocytes
91. Activation of rabbit liver high affinity cAMP (type IV) phosphodiesterase by a vanadylglutathione complex. Characterization of the role of the sulfhydryl
92. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
93. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
94. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
95. Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III
96. Inhibition of lipid accumulation and enhancement of energy expenditure by the addition of pyruvate and dihydroxyacetone to a rat diet
97. Body composition, energy utilization, and nitrogen metabolism with a severely restricted diet supplemented with dihydroxyacetone and pyruvate
98. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate
99. Inhibition of regain in body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeeding after weight reduction
100. The effects of pyruvate supplementation on body composition in overweight individuals
101. Induction of hepatic mitochondrial glycerophosphate dehydrogenase in rats by dehydroepiandrosterone
102. Rat mitochondrial glycerol-3-phosphate dehydrogenase gene: Multiple promoters, high levels in brown adipose tissue, and tissue- specific regulation by thyroid hormone
103. Treatment of obesity. Current data on TRIAC
104. Organ-specific effects of 3,5,3′-triiodothyroacetic acid in rats
105. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone
106. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine
107. Induction of thermogenic enzymes by DHEA and its metabolites
108. Ergosteroids: Induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone
109. Dehydroepiandrosterone and body fat
110. Iron is the intracellular metal involved in the production of DNA damage by oxygen radicals
111. Vegetarians and vegans may be most at risk from low selenium intakes
112. Thyroid hormone-independent regulation of mitochondrial glycerol-3-phosphate dehydrogenase by the peroxisome proliferator clofibric acid
113. Thyromimetic effect of peroxisomal proliferators in rat liver
114. Enhancement of NAD-linked isocitrate dehydrogenase activity in rat liver by clofibrate feeding
115. The antiobesity effect of dehydroepiandrosterone in rats
116. Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats
117. Inhibition of lipid synthesis by beta beta′-tetramethyl-substituted. C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes
118. Inhibition of rat liver acetyl-CoA carboxylase by beta, beta′-tetramethyl-substituted hexadecanedioic acid (MEDICA 16)
119. Hypolipidemic, antiobesity, and hypoglycemic-hypoinsulinemic effects of beta, beta′-methyl-substituted hexadecanedioic acid in sand rats
120. Adipose reduction by beta, beta′-tetramethyl-substituted hexadecanedioic acid (MEDICA 16)
121. Metabolic origins of thermogenesis induced by diet
122. Characteristics of thyroid-function in experimental protein malnutrition
123. Dietary carbohydrate and fat do not alter the thyroid response to protein deficiency in chicks
124. Gluttony and thermogenesis revisited
125. Gluttony. 2. Thermogenesis in overeating man
126. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity
127. Postingestional effects of a high-protein diet on the regulation of food intake in monkeys
128. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity
129. Chemoprotection against cancer by phase 2 enzyme induction
130. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans
131. Anti-obesity action of oolong tea
132. Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet
133. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats
134. Hypocholesterolemic effects of Chinese tea
135. Effect of green and black tea supplementation on lipids, lipid oxidation and fibrinogen in the hamster: Mechanisms for the epidemiological benefits of tea drinking
136. Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice
137. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha
138. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat
139. Dietary conjugated linoleic acid reciprocally modifies ketogenesis and lipid secretion by the rat liver
140. Effect of conjugated linoleic acid on body composition in mice
141. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse
142. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake
143. Dietary conjugated linoleic acids increase lean tissue and decrease fat deposition in growing pigs
144. Dietary effect of conjugated linoleic acid on lipid levels in white adipose tissue of Sprague-Dawley rats
145. Thyroxine-induced changes in rat liver mitochondrial ubiquinone
146. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study
147. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin
148. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease
149. Co-enzyme Q10: A new drug for cardiovascular disease
150. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials
151. Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics
152. Biotin enhances guanylate cyclase activity
153. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes
154. Transcriptional regulation of the glucokinase gene by biotin in starved rats
155. Transcriptional regulation of liver phosphoenolpyruvate carboxykinase by biotin in diabetic rats
156. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy of type II diabetes
157. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin-dependent diabetes mellitus
158. Biotin status and plasma glucose in diabetics
159. Biotin supplementation improves glucose and insulin tolerances in genetically diabetic KK mice
160. Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats
161. A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus
162. Metabolic effects of metformin in non-insulin- dependent diabetes mellitus
163. Management of obesity in NIDDM (non-insulin-dependent diabetes mellitus)
164. The impact of pharmacotherapy on weight management in type 2 diabetes
165. Observations on the mechanism of increased weight loss during metformin administration in obesity
166. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
167. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
168. Long-term use of a high-complex-carbohydrate, high-fiber, low-fat diet and exercise in the treatment of NIDDM patients